Founded in 2006, Zogenix Inc. is a privately held, specialty pharmaceutical company. It develops and commercializes differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. Zogenix Inc has received approval from the Food and Drug Administration (FDA) for SUMAVEL DosePro (sumatriptan injection) needle-free delivery system, which is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the treatment of acute migraine and cluster headache. The company s other product, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. Zogenix Inc. is supported by several investors, including Abingworth Management Ltd., Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partner and others.